Eladynos

RSS

abaloparatide

Authorised
This medicine is authorised for use in the European Union.

Overview

Eladynos is a medicine used to treat osteoporosis (a disease that makes bones fragile) in women who have been through menopause and are at increased risk of bone fractures.

This medicine contains the active substance abaloparatide.

This EPAR was last updated on 22/12/2022

Authorisation details

Product details
Name
Eladynos
Agency product number
EMEA/H/C/005928
Active substance
abaloparatide
International non-proprietary name (INN) or common name
abaloparatide
Therapeutic area (MeSH)
  • Osteoporosis, Postmenopausal
  • Osteoporosis
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Radius Health Ireland Ltd
Contact address

13 Classon House
Dublin
W973
Ireland

Product information

12/12/2022 Eladynos - EMEA/H/C/005928 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Assessment history

How useful was this page?

Add your rating